Deals
Going private could give Recordati strategic flexibility and a stable source of capital, according to CVC Capital Partners and Groupe Bruxelles Lambert, which are offering to take the Italian pharma private for a 13% premium.
FEATURED STORIES
European pharma companies splashed billions of dollars into the U.S. biopharma sector in a matter of days, but there are differing views on whether the activity represents the rise of a new buyer class or a quirk of timing.
After years of suffering from a bear market and more than 14 months of geopolitical turmoil shaking the macroenvironment, biotech appears to be moving on.
With six acquisitions already this year, Eli Lilly’s business development shows no signs of stopping as executives make good on a promise to spend their GLP-1 gains.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
South San Francisco-based RAPT Therapeutics announced it is postponing its initial public offering (IPO) it filed earlier to raise $86 million via selling 5 million shares at $14 to $16 per share. No reasons were given for the postponement.
Ultragenyx Pharmaceutical Inc. reported its financial results and corporate update for the quarter ended June 30, 2019.
FUJIFILM Corporation announced that it has completed the acquisition of Biogen Manufacturing ApS, a large-scale biologics manufacturing site located in Hillerød near Copenhagen, Denmark from Biogen.
Great Bay Bio, a leading biotechnology company dedicated to innovative biologics CMC (Chemistry Manufacturing and Controls) and development of biologics development big data platform, the board is pleased to announce the introduction of a new non-executive director, Mr. William Kung.
Neos Therapeutics, Inc. announced that it will report its second quarter 2019 financial results prior to the opening of U.S. financial markets on Thursday, August 8, 2019.
Clinical stage cannabinoid company Botanix Pharmaceuticals Limited is pleased to announce the receipt of firm commitments in respect of a A$40m placement led by specialist US-based biotech investment funds and leading US institutional investors, as well as the appointment of two new experienced dermatology executives.
MyoKardia, Inc., announced that it will report second quarter 2019 financial and operating results on Wednesday, August 7, 2019.
Catalyst Pharmaceuticals, Inc. announced that it will release second quarter 2019 financial result after market close on Wednesday, August 7, 2019.
Proceeds will be used to grow company’s team in Lyon and Boston, to advance its current programs in hypoparathyroidism and severe insulin resistance into clinical development, and to further strengthen its product portfolio in rare endocrine and metabolic diseases
Esperion announced it will report second quarter 2019 financial results on August 8, 2019 before the U.S. financial markets open.